Please login to the form below

Not currently logged in
Email:
Password:

Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

She arrives from US-based Dimension Therapeutics, where she was CEO

Annalisa JenkinsUK-based PlaqueTec has appointed Annalise Jenkins as its chief executive officer, a role that will see her lead the 2018 launch of the biomarker-based liquid biopsy system (LBS).

Dr Jenkins joins the company from Dimension Therapeutics, where she served as its chief executive officer, and her previous roles have seen her gain expertise in scientific research, clinical development, regulatory process and commercialisation.

Jon Moynihan, chairman of PlaqueTec, said: “Dr Jenkins is a passionate and energetic leader with a proven track record of successfully translating exciting science from bench to bedside.

“We are pleased to welcome her to PlaqueTec at an important time for the company, as we will surely benefit from her extensive expertise in growing both private and public companies in the life sciences industry.”

Prior to Dimension Therapeutics, Dr Jenskins served as executive vice president, head of global research and development for Merck Serono and she has also had a nearly 15-year career at Bristol-Myers Squibb.

She said: “I look forward to working with the highly accomplished leadership team and board of directors at PlaqueTec to help advance the study and launch of its pioneering system through increased academic and biopharma collaborations.”

22nd November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics